Abstract:Chimeric antigen receptor (CAR) T cell therapy, while highly efficacious for the treatment of certain haematological malignancies, remains ineffective in solid cancers. This can be attributed to various factors, including immunosuppression and heterogeneous expression of targetable tumor antigens. Our previous work (Lai et al. 2020, Nature Immunology) demonstrated that engineering CAR T cells to engage host immunity is key to effectively treating heterogenous tumors. "Armouring" CAR T cells to express proinflammatory cytokines is a promising strategy to engage endogenous anti-tumor immunity. However, conventional armouring approaches that utilize a synthetic promoter to drive cytokine expression (e.g. NFAT promoter) lead to systemic expression of transgenes, which can cause severe clinical toxicities when potent cytokines such as IL-12 are employed. In the current work, we engineered CAR T cells to express anti-tumor factors under the transcriptional control of tumor-specific promoters, and hypothesised that this would enhance the safety and efficacy of armoured CAR T cells (Chen et al. in revision, Cell). Genome-wide RNA-sequencing was used to identify genes in CAR T cells with tumor-specific expression. A novel CRISPR/Cas9-mediated homology directed repair strategy was then employed to knock in (KI) anti-cancer factors into these gene loci. NR4A2 was identified as the promoter with the highest degree of tumor-site restriction and T cells were subsequently engineered to express cytokines from this promoter. This approach was applied to syngeneic CAR T and OT-I murine models that enable clinically relevant assessment of efficacy and safety. CRISPR-engineered primary murine and human CAR T cells exhibited gene KI efficiency of ∼50%. Integrating proinflammatory cytokines such as IL-12 into the NR4A2 promoter led to antigen-specific induction of transgene expression in tumor cocultures, and tumor-restricted expression in vivo. Importantly, this strategy achieved significantly improved tumor-site specific expression of transgenes relative to the NFAT promoter system. Tumor-specific induction of IL-12 improved anti-tumor efficacy leading to eradication of established tumors and activation of host immunity/epitope spreading that enabled effective treatment of heterogenous tumors. Importantly, this approach did not lead to significant systemic expression of IL-12, and provided a favourable safety profile. We were able to demonstrate that this approach was equally scalable as conventional CAR T cell generation protocols and could be applied to either autologous patient-derived CAR T cells or through a CRISPR Knock-In approach to generate CAR T from allogenic health donor-derived PBMCs. We therefore posit that this technology has the potential to enable the armoring of CAR T cells with cargos that are highly potent and require exquisite tumor-site specific expression of transgenes. Citation Format: Paul Beavis. CRISPR/Cas9 Engineering of Next-Generation Armoured CAR T Cells [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr PR-02.

Cas9-cleavage sequences in minimal plasmids enhance non-viral genome targeting of CARs in primary human T cells

Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells.

CRISPR-Cas12a System With Synergistic Phage Recombination Proteins for Multiplex Precision Editing in Human Cells

Non-viral expression of chimeric antigen receptors with multiplex gene editing in primary T cells

CRISPR/Cas-based CAR-T cells: production and application

An aptamer-mediated base editing platform for simultaneous knockin and multiple gene knockout for allogeneic CAR-T cells generation

Lipid Nanoparticle-Mediated Gene Editing of Human Primary T Cells and Off-Target Analysis of the CRISPR-Cas9 Indels

Abstract 2840: Identification of a safe harbor CRISPR-Cas9 integration site for improved cell therapy safety and potency

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy

Efficient Generation of Locus-Specific Human CAR-T Cells with CRISPR/cCas12a

Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes

Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing

Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells

Cas9 Ribonucleoprotein Delivery Via Microfluidic Cell-Deformation Chip for Human T-Cell Genome Editing and Immunotherapy.

AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines

Integration of ζ-deficient CARs into the CD3-zeta gene conveys potent cytotoxicity in T and NK cells

Generating universal anti-CD19 CAR T cells with a defined memory phenotype by CRISPR/Cas9 editing and safety evaluation of the transcriptome

Abstract PR-02: CRISPR/Cas9 Engineering of Next-Generation Armoured CAR T Cells

One-step generation of modular CAR-T cells with AAV-Cpf1

In vivo human T cell engineering with enveloped delivery vehicles

Tropism-facilitated delivery of CRISPR/Cas9 system with chimeric antigen receptor-extracellular vesicles against B-cell malignancies